Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTH522 + aluminum hydroxide
- Development stage
- Unknown
- Lead developer
- Statens Serum Institut
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CTH522 + aluminum hydroxide is a vaccine candidate for the prevention of Chlamydia trachomatis infections. It consists of CTH522, a recombinant chimeric protein containing portions of the C. trachomatis major outer membrane protein (MOMP), adjuvanted with aluminum hydroxide. The CTH522 component combines a partial sequence of MOMP from serovar D with external domains from serovars E, F, and G, representing the most prevalent Chlamydia serovars.
- Other names
- CTH522/AlOH
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on CTH522 + aluminum hydroxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTH522 + aluminum hydroxide.